Keryx Biopharmaceuticals Inc. is a Boston-based biopharmaceutical company working in the field of renal diseases.
The company’s only marketed product, Auryxia (ferric citrate) was approved in the U.S. in Sep 2014 for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. In Sep 2015, Keryx gained EU approval for Fexeric (EU trade name for Auryxia) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adult patients with CKD, including dialysis and non-dialysis dependent CKD. Keryx’s top line comprises license revenues and revenues earned from Auryxia sales.
In August 2016, Keryx announced an interruption in the supply of Auryxia, as its contract manufacturer had issues related to the conversion of the API into the finished product, leading to a disruption in the supply of Auryxia. However, in Nov 2016, Keryx announced that the FDA has approved a second drug product manufacturer, Patheon Manufacturing Services, for supplying Auryxia as a finished product. Following the approval, the company has rebuilt supply and made Auryxia available to wholesalers. In Mar 2017, FDA accepted the company’s supplemental New Drug Application (sNDA) for Auryxia for review and given a Prescription Drug User Fee Act (PDUFA) target action date of Nov 6, 2017.Keryx’s earnings track record has been disappointing so far. Over the four trailing quarters, the company has posted an average negative earnings surprise of 35.16%.
Currently, Keryx has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Keryx’s first-quarter 2017 loss was wider-than-expected. The company posted a loss of 21 cents per share wider than consensus estimate of a loss of 18 cents.
Revenues: Revenues, however, surpassed expectations. Keryx posted revenues of $11.8 million above the consensus estimate of $10.11 million.
Key Stats:Auryxia net U.S. product sales came in at $10.5 million, up 87.5% from the year-ago quarter.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on KERX earnings report later!
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Image: Bigstock
Keryx (KERX) Posts Wider-than-Expected Q1 Loss, Sales Beat
Keryx Biopharmaceuticals Inc. is a Boston-based biopharmaceutical company working in the field of renal diseases.
The company’s only marketed product, Auryxia (ferric citrate) was approved in the U.S. in Sep 2014 for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. In Sep 2015, Keryx gained EU approval for Fexeric (EU trade name for Auryxia) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adult patients with CKD, including dialysis and non-dialysis dependent CKD. Keryx’s top line comprises license revenues and revenues earned from Auryxia sales.
In August 2016, Keryx announced an interruption in the supply of Auryxia, as its contract manufacturer had issues related to the conversion of the API into the finished product, leading to a disruption in the supply of Auryxia. However, in Nov 2016, Keryx announced that the FDA has approved a second drug product manufacturer, Patheon Manufacturing Services, for supplying Auryxia as a finished product. Following the approval, the company has rebuilt supply and made Auryxia available to wholesalers. In Mar 2017, FDA accepted the company’s supplemental New Drug Application (sNDA) for Auryxia for review and given a Prescription Drug User Fee Act (PDUFA) target action date of Nov 6, 2017.Keryx’s earnings track record has been disappointing so far. Over the four trailing quarters, the company has posted an average negative earnings surprise of 35.16%.
Currently, Keryx has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Keryx’s first-quarter 2017 loss was wider-than-expected. The company posted a loss of 21 cents per share wider than consensus estimate of a loss of 18 cents.
Revenues: Revenues, however, surpassed expectations. Keryx posted revenues of $11.8 million above the consensus estimate of $10.11 million.
Key Stats:Auryxia net U.S. product sales came in at $10.5 million, up 87.5% from the year-ago quarter.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on KERX earnings report later!
Keryx Biopharmaceuticals, Inc. Price and EPS Surprise
Keryx Biopharmaceuticals, Inc. Price and EPS Surprise | Keryx Biopharmaceuticals, Inc. Quote
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>